ERBB2 and neoplasm: In a second study the in vivo activity of Her2-bridging CAR-CD19 T cells and CAR-Her2 T cells (CAR-390, Table 1) was compared and we found that the tumor control curves and the survival curves were indistinguishable (Fig 5D and 5E).